[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.179.232. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 9,386
Citations 0
Editorial
January 3, 2017

Scientific Evidence and Financial Obligations to Ensure Access to Biosimilars for Cancer Treatment

Author Affiliations
  • 1Editor in Chief, JAMA
  • 2Executive Editor, JAMA
  • 3Deputy Editor, JAMA
JAMA. 2017;317(1):33-34. doi:10.1001/jama.2016.18743

Articles in medical journals add to the scientific body of research that ultimately influences care. On rare occasions a single study changes the practice of medicine, but in general most clinical research reports contribute to a body of evidence that becomes part of the fabric of clinical decision making, including individual decisions of physicians and patients as well as use in guidelines and recommendations of professional societies and governmental agencies.

In this issue of JAMA, Rugo and colleagues1 report findings from a multicenter clinical trial that may influence care for patients with breast cancer around the world. The authors evaluated the equivalence of a proposed trastuzumab biosimilar compared with the standard therapy, the humanized monoclonal antibody trastuzumab, for achieving overall response and for safety among 458 women without prior treatment for ERBB2 (HER2)–positive metastatic breast cancer.

First Page Preview View Large
First page PDF preview
First page PDF preview
×